SC
GILD icon

Sculptor Capital’s Gilead Sciences GILD Stock Holding History

Sculptor Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-204,200
Closed -$20M – 428
2015
Q1 		$20M Buy
+204,200
New +$20.7M 0.07% 164

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sculptor Capital's GILD Position: Q2 2015 in Review

Sculptor Capital sold out of Gilead Sciences (GILD) in Q2 2015, closing a stake of 204,200 shares — an estimated $20M sold.

Sculptor Capital first reported a position in GILD in Q1 2015 and held it in 1 quarter. The position peaked at $20M in Q1 2015. 1,559 funds tracked by Wall St. Rank hold GILD as of Q2 2015.

  • Sculptor Capital reported no remaining Gilead Sciences position as of Q2 2015 after selling out during the quarter.
  • Sculptor Capital sold 204,200 Gilead Sciences shares in Q2 2015, an estimated $20M.
  • Sculptor Capital first reported a position in Gilead Sciences in Q1 2015 and held it in 1 quarter.
  • Sculptor Capital's Gilead Sciences position peaked at $20M in Q1 2015.
  • 1,559 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2015.

Based on Sculptor Capital's 13F filing for Q2 2015, filed 14 Aug 2015.